189 related articles for article (PubMed ID: 29574193)
21. A randomized phase I study comparing the pharmacokinetics of a bevacizumab (HD204) biosimilar to European Union- and United States of America-sourced bevacizumab.
Demarchi M; Coliat P; Barthelemy P; Schott R; BenAbdelghani M; Kim M; Hii JCS; Feyaerts P; Ang FRX; Derde MP; Deforce F; Petit T; Schwabe C; Wynne C; Park LS; Pivot X
PLoS One; 2021; 16(9):e0248222. PubMed ID: 34555031
[TBL] [Abstract][Full Text] [Related]
22. Charge Variants of an Avastin Biosimilar Isolation, Characterization, In Vitro Properties and Pharmacokinetics in Rat.
Zhao YY; Wang N; Liu WH; Tao WJ; Liu LL; Shen ZD
PLoS One; 2016; 11(3):e0151874. PubMed ID: 26987122
[TBL] [Abstract][Full Text] [Related]
23. Effect of nanoencapsulation using poly (lactide-co-glycolide) (PLGA) on anti-angiogenic activity of bevacizumab for ocular angiogenesis therapy.
Zhang XP; Sun JG; Yao J; Shan K; Liu BH; Yao MD; Ge HM; Jiang Q; Zhao C; Yan B
Biomed Pharmacother; 2018 Nov; 107():1056-1063. PubMed ID: 30257317
[TBL] [Abstract][Full Text] [Related]
24. A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men.
Markus R; Chow V; Pan Z; Hanes V
Cancer Chemother Pharmacol; 2017 Oct; 80(4):755-763. PubMed ID: 28864922
[TBL] [Abstract][Full Text] [Related]
25. SB8: A Bevacizumab Biosimilar.
Syed YY
Target Oncol; 2020 Dec; 15(6):787-790. PubMed ID: 33206282
[TBL] [Abstract][Full Text] [Related]
26. Analytical Similarity of a Proposed Biosimilar BVZ-BC to Bevacizumab.
Yu C; Zhang F; Xu G; Wu G; Wang W; Liu C; Fu Z; Li M; Guo S; Yu X; Wang L
Anal Chem; 2020 Feb; 92(4):3161-3170. PubMed ID: 31983199
[TBL] [Abstract][Full Text] [Related]
27. Bevacizumab biosimilars: scientific justification for extrapolation of indications.
Melosky B; Reardon DA; Nixon AB; Subramanian J; Bair AH; Jacobs I
Future Oncol; 2018 Oct; 14(24):2507-2520. PubMed ID: 29690784
[TBL] [Abstract][Full Text] [Related]
28. IBI302, a promising candidate for AMD treatment, targeting both the VEGF and complement system with high binding affinity in vitro and effective targeting of the ocular tissue in healthy rhesus monkeys.
Ren X; Li J; Xu X; Wang C; Cheng Y
Exp Eye Res; 2016 Apr; 145():352-358. PubMed ID: 26919788
[TBL] [Abstract][Full Text] [Related]
29. Comparative safety assessments of the biosimilar APZ001 and Erbitux in pre-clinical animal models.
Wang X; Guo J; Deng X; Huang Y; Ye C; Liang H; Rao J; Yang W
Acta Cir Bras; 2018 Aug; 33(8):690-702. PubMed ID: 30208131
[TBL] [Abstract][Full Text] [Related]
30. The effect of paclitaxel and nab-paclitaxel in combination with anti-angiogenic therapy in breast cancer cell lines.
Tonissi F; Lattanzio L; Merlano MC; Infante L; Lo Nigro C; Garrone O
Invest New Drugs; 2015 Aug; 33(4):801-9. PubMed ID: 25947567
[TBL] [Abstract][Full Text] [Related]
31. Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer.
Loizzi V; Del Vecchio V; Gargano G; De Liso M; Kardashi A; Naglieri E; Resta L; Cicinelli E; Cormio G
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28906427
[TBL] [Abstract][Full Text] [Related]
32. A randomized, single-blind, Phase I trial (INVICTAN-1) assessing the bioequivalence and safety of BI 695502, a bevacizumab biosimilar candidate, in healthy subjects.
Hettema W; Wynne C; Lang B; Altendorfer M; Czeloth N; Lohmann R; Athalye S; Schliephake D
Expert Opin Investig Drugs; 2017 Aug; 26(8):889-896. PubMed ID: 28651442
[TBL] [Abstract][Full Text] [Related]
33. Gastrointestinal cancer cells treatment with bevacizumab activates a VEGF autoregulatory mechanism involving telomerase catalytic subunit hTERT via PI3K-AKT, HIF-1α and VEGF receptors.
Mahfouz N; Tahtouh R; Alaaeddine N; El Hajj J; Sarkis R; Hachem R; Raad I; Hilal G
PLoS One; 2017; 12(6):e0179202. PubMed ID: 28594907
[TBL] [Abstract][Full Text] [Related]
34. An update on the animal studies conducted for biosimilar approvals - Regulatory requirement vs actual scenario.
Pipalava P; Patel R; Mehta M; Dahiya M; Singh I; Jose V
Regul Toxicol Pharmacol; 2019 Oct; 107():104415. PubMed ID: 31254556
[TBL] [Abstract][Full Text] [Related]
35. Biological Characterization of SB3, a Trastuzumab Biosimilar, and the Influence of Changes in Reference Product Characteristics on the Similarity Assessment.
Lee JH; Paek K; Moon JH; Ham S; Song J; Kim S
BioDrugs; 2019 Aug; 33(4):411-422. PubMed ID: 31190280
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic and toxicology comparator testing of biosimilar drugs - Assessing need.
Baldrick P
Regul Toxicol Pharmacol; 2017 Jun; 86():386-391. PubMed ID: 28433587
[TBL] [Abstract][Full Text] [Related]
37. FDA's Approval of the First Biosimilar to Bevacizumab.
Casak SJ; Lemery SJ; Chung J; Fuchs C; Schrieber SJ; Chow ECY; Yuan W; Rodriguez L; Gwise T; Rowzee A; Lim S; Keegan P; McKee AE; Pazdur R
Clin Cancer Res; 2018 Sep; 24(18):4365-4370. PubMed ID: 29743182
[TBL] [Abstract][Full Text] [Related]
38. Inhibitory effect of bevacizumab on the angiogenesis and growth of retinoblastoma.
Lee SY; Kim DK; Cho JH; Koh JY; Yoon YH
Arch Ophthalmol; 2008 Jul; 126(7):953-8. PubMed ID: 18625942
[TBL] [Abstract][Full Text] [Related]
39. A randomized study comparing the pharmacokinetics of the potential biosimilar PF-06438179/GP1111 with Remicade® (infliximab) in healthy subjects (REFLECTIONS B537-01).
Palaparthy R; Udata C; Hua SY; Yin D; Cai CH; Salts S; Rehman MI; McClellan J; Meng X
Expert Rev Clin Immunol; 2018 Apr; 14(4):329-336. PubMed ID: 29504427
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of differential toxicity of varying doses of bevacizumab on retinal ganglion cells, retinal pigment epithelial cells, and vascular endothelial growth factor-enriched choroidal endothelial cells.
Brar VS; Sharma RK; Murthy RK; Chalam KV
J Ocul Pharmacol Ther; 2009 Dec; 25(6):507-11. PubMed ID: 20028259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]